HANXBIO-B (03378) announced its full-year financial results for the fiscal year ended December 31, 2025. The Group reported other income and gains of 16.616 million yuan, representing a year-on-year increase of 116.33%. Research and development expenses amounted to 89.363 million yuan, an increase of 19.6% compared to the previous year. The net loss for the period was 131 million yuan, widening by 12.46% year-on-year.
The company's core competitiveness stems from its focus on unique biological principles and two proprietary innovative platforms: the VersatiBody™ multi-functional antibody platform and the autoRx40™ autoimmune therapy platform. These platforms synergistically drive the efficient development and output of differentiated drug candidates. Furthermore, through a dual-strategy model combining internal R&D and external strategic collaborations, the company continuously enriches its product pipeline, accelerates clinical development, and amplifies the commercial value of its technology platforms.
As of December 31, 2025, the company has established a tiered product pipeline consisting of "clinical-stage (3 assets) + IND-approved stage (1 asset) + preclinical-stage (multiple assets)". Key assets, including a tumor immunotherapy bispecific antibody and an OX40-targeted ADC, possess global first-in-class potential, laying a solid product foundation for the company's long-term development.
Throughout 2025, the company achieved several key milestones related to pipeline advancement, technological platform iteration, and global strategy. The initial validation of the clinical value of its core assets has created阶段性 value for shareholders.
Comments